Compare AYTU & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYTU | AQMS |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 20.9M |
| IPO Year | N/A | 2015 |
| Metric | AYTU | AQMS |
|---|---|---|
| Price | $2.33 | $6.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $9.33 | ★ $12.00 |
| AVG Volume (30 Days) | 52.7K | ★ 162.4K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $63,696,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $47.30 | $550.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.95 | $3.37 |
| 52 Week High | $2.82 | $39.40 |
| Indicator | AYTU | AQMS |
|---|---|---|
| Relative Strength Index (RSI) | 60.88 | 43.74 |
| Support Level | $2.05 | $6.93 |
| Resistance Level | $2.39 | $7.61 |
| Average True Range (ATR) | 0.10 | 0.59 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 78.57 | 0.00 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.